[A20-22] Ribociclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V
Last updated 20.08.2020
Project no.:
A20-22
Commission:
Commission awarded on 02.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-21 | Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-06 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-45 | Ribociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-58 | Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22 | Commission completed |
Federal Joint Committee (G-BA)
2020-08-20: A G-BA decision was published.